Glenmark settles bulk of major US litigations.

Glenmark Pharmaceuticals Limited GLENMARK said the bulk of its major litigations in America are now settled. This removes a key overhang for the company. Most major litigations in the US have been settled. The resolution clears a significant uncertainty for the firm. It allows management to focus more on core operations and growth in the pharma sector. The key trigger is the settlement of the bulk of major US litigations. This may support near-term interest in the stock by reducing legal risk. Peers such as Sun Pharma, Dr. Reddy's Laboratories and Cipla could face relative comparison on litigation outcomes. Risks include any remaining cases or related costs. Competitors listed: Sun Pharma, Dr. Reddy's Laboratories, Cipla. We have no financial interest in this news.